Go Pro
→ He bet half his $9 billion on ONE stock (From Stansberry Research) (Ad)tc pixel
NASDAQ:CCCC

C4 Therapeutics Q2 2026 Earnings Report

C4 Therapeutics logo
$3.50 +0.02 (+0.57%)
Closing price 08/3/2026 04:00 PM Eastern
Extended Trading
$3.51 +0.01 (+0.29%)
As of 08:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

C4 Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.23
Beat/Miss
N/A
One Year Ago EPS
N/A

C4 Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$8.20 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

C4 Therapeutics Announcement Details

Quarter
Q2 2026
Date
8/6/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

C4 Therapeutics Earnings Headlines

Brokerages Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target at $7.75
July 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30932205
Vericel (NASDAQ:VCEL) versus C4 Therapeutics (NASDAQ:CCCC) Financial Survey
July 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30919832
He bet half his $9 billion on ONE stock
One of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund - into a single, little-known company. His firm then bought more shares for 61 straight trading days, and the former CEO of Google soon struck a nine-figure partnership with the same company. This company controls nearly a million acres of scarce, irreplaceable minerals now protected by a White House executive order signed January 14, 2026. It has already outperformed Apple, Amazon, and the S-P 500 combined - and Whitney Tilson believes the biggest gains are still ahead.tc pixel
August 4 at 1:00 AM  |  Stansberry Research (Ad)
C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?
July 3, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/c4-therapeutics-cccc-gains-over-the-past-month-can-it-go-higher-1794187/
C4 Therapeutics Shareholders Back Directors, Pay and Auditors
June 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/c4-therapeutics-shareholders-back-directors-pay-and-auditors?utm_source=marketbeat.com&utm_medium=referral
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - Slideshow
June 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4916492-c4-therapeutics-inc-cccc-discusses-evolving-multiple-myeloma-treatments-and-the-role-of-ikzf1
See More C4 Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like C4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on C4 Therapeutics and other key companies, straight to your email.

About C4 Therapeutics

C4 Therapeutics (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages. Lead programs are directed at hematologic malignancies, solid tumors and other serious diseases. C4 Therapeutics has established strategic collaborations with major pharmaceutical partners to leverage its CiD platform across various therapeutic areas. These partnerships provide access to joint research and development resources, accelerating the advancement of novel degrader molecules into human studies.

Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics operates research laboratories in the United States and collaborates with academic institutions and contract research organizations worldwide. The company employs a multidisciplinary team of chemists, biologists and drug development experts to drive its discovery engine and translate early-stage assets into clinical candidates.

C4 Therapeutics is led by a management team with extensive experience in protein chemistry, drug discovery and clinical development. The company’s leadership includes seasoned biotechnology executives and scientific advisors who guide its efforts to bring next-generation protein degraders to patients. Through its innovative platform, C4 Therapeutics aims to expand the therapeutic possibilities for diseases driven by previously “undruggable” targets.

View C4 Therapeutics Profile
Earnings Tools